Jiyong Wu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Vascular Endothelial Growth Factor

Top Venues

Cost effectiveness and resource allocation : C/E

Mini reviews in medicinal chemistry

Future oncology (London, England)

Chemical communications (Cambridge, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Jing Nie, Huina Wu, Yepeng Luan, Jiyong Wu
The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy. Mini reviews in medicinal chemistry (2023)
Jing Nie, Huina Wu, Qian Wu, Qi Liu, Lihui Liu, Jiyong Wu
Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients. Future oncology (London, England) (2023)
Di Zhang, Jing Nie, Dongbo Wang, Huina Wu, Lei Sun, Xuejian Wang, Jiyong Wu
Engineering a multi-target therapy nanoplatform against tumor growth and metastasis via a novel NSAID-Pt(IV) prodrug. Chemical communications (Cambridge, England) 58 (23) (2022)